产品
编 号：F415882
分子式：C11H8Cl2N2O2
分子量：271.1
分子式：C11H8Cl2N2O2
分子量：271.1
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 646530-37-2
产品详情
生物活性：
UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors.
体内研究：
UTL-5g (GBL-5g) lowers levels of TGF-β and TNF-α elevated by lung irradiation.UTL-5g (60 mg/kg; p.o.; daily for 4 days) shows positive effects in increasing the survival rates and extending the survival times.Animal Model:C57BL/6, male mice (8-10 weeks)
Dosage:15, 30, and 60 mg/kg
Administration:I.p.; before irradiation, daily x 5
Result:Blood levels of TGF-β were lowered.
Animal Model:BDF1 female mice
Dosage:P.o.; daily for 4 days
Administration:60 mg/kg (30 min before i.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on Day 0)
Result:Increased the survival rate and delayed the time to death for mice treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death.
体外研究：
RAW 264.7 macrophages are transfected with the respective reporter assay plasmids, pretreated with UTL-5g at 1, 10 or 50 μM for 60 min and then challenged with 100 ng/ml LPS. After a 16 h incubation, transcription factor activity is measured. Transcription factors that shows a UTL-5g dose-dependent decrease in activity in two experiments are categorized as being disrupted by UTL-5g.
UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors.
体内研究：
UTL-5g (GBL-5g) lowers levels of TGF-β and TNF-α elevated by lung irradiation.UTL-5g (60 mg/kg; p.o.; daily for 4 days) shows positive effects in increasing the survival rates and extending the survival times.Animal Model:C57BL/6, male mice (8-10 weeks)
Dosage:15, 30, and 60 mg/kg
Administration:I.p.; before irradiation, daily x 5
Result:Blood levels of TGF-β were lowered.
Animal Model:BDF1 female mice
Dosage:P.o.; daily for 4 days
Administration:60 mg/kg (30 min before i.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on Day 0)
Result:Increased the survival rate and delayed the time to death for mice treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death.
体外研究：
RAW 264.7 macrophages are transfected with the respective reporter assay plasmids, pretreated with UTL-5g at 1, 10 or 50 μM for 60 min and then challenged with 100 ng/ml LPS. After a 16 h incubation, transcription factor activity is measured. Transcription factors that shows a UTL-5g dose-dependent decrease in activity in two experiments are categorized as being disrupted by UTL-5g.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备